Blockchain Registration Transaction Record

Lantern Pharma to Present AI Cancer Breakthroughs at ThinkEquity Conference

Lantern Pharma (NASDAQ: LTRN) announces presentation at ThinkEquity Conference showcasing AI-driven cancer drug discovery platform with $15B market potential and advanced clinical pipeline.

This announcement matters because Lantern Pharma represents the cutting edge of how artificial intelligence is revolutionizing cancer treatment development. Traditional drug discovery can take over a decade and cost billions, but AI platforms like RADR® are dramatically accelerating this process while reducing costs. For cancer patients, this means potentially life-saving treatments could reach the market years faster. For investors, it showcases how AI is transforming biotech valuation models and creating new investment opportunities in precision medicine. The company's $15 billion market potential estimate reflects the massive unmet need in oncology and the financial upside of successful AI-driven drug development.